{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-001971","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.908971+00:00","generated_at":"2026-05-16T10:40:55.131906+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Co-Diagnostics receives Nasdaq delisting notice; trading to move to OTC Pink effective Jan 14","bullets":["Nasdaq Staff determined to delist CODX due to continued non-compliance with minimum bid price rule.","Trading on Nasdaq suspended from open on Jan 14, 2026; shares expected to trade on OTC Pink under CODX.","Company plans to request a hearing with Nasdaq Hearings Panel to address bid price deficiency.","Since Jan 2, 2026 (1-for-30 reverse split effective), bid price closed at or above $1.00; may seek compliance if 10 consecutive days ending Jan 15 show $1.00.","Prior non-compliance notice Jan 10, 2025; two compliance periods expired Jan 5, 2026 without meeting rule."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-001971","json":"https://secwatch.observer/filing/0001493152-26-001971.json","markdown":"https://secwatch.observer/filing/0001493152-26-001971.md","text":"https://secwatch.observer/filing/0001493152-26-001971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/0001493152-26-001971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:40:55.131906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"261b568cd7b2030ed2d81edf468a4a8fc6e8b314","claim":"Co-Diagnostics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5815(a)(1)(B)(ii)(d)).","evidence_excerpt":"January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company plans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s securi","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/0001493152-26-001971-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-062844","ticker":"ADTX","company_name":"Aditxt, Inc.","filed_at":"2026-05-29T20:21:24+00:00","headline":"Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062844","json":"https://secwatch.observer/filing/0001213900-26-062844.json","markdown":"https://secwatch.observer/filing/0001213900-26-062844.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/0001213900-26-062844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/ea0292786-8k_aditxt.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing\nQualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that\nthe Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued\nnon-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company\nplans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s\nsecuri","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/0001493152-26-001971-index.htm","comparable_excerpt":"May 27, 2026, Aditxt, Inc. (the “Company”)\nreceived a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market\nLLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s\nQuarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum\nstockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1)\n(the “Stockholders’ Equity Requirement”). The Letter further","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/0001213900-26-062844-index.htm"}},{"accession":"0001104659-26-066974","ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-05-27T20:30:41+00:00","headline":"Liminatus Pharma receives Nasdaq delisting notice; appeals filed","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-066974","json":"https://secwatch.observer/filing/0001104659-26-066974.json","markdown":"https://secwatch.observer/filing/0001104659-26-066974.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/0001104659-26-066974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/tm2615785d1_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing\nQualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that\nthe Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued\nnon-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company\nplans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s\nsecuri","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/0001493152-26-001971-index.htm","comparable_excerpt":"May 20, 2026, the Company received a notice\nfrom Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will\nbe delisted from The Nasdaq Global Mark","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/0001104659-26-066974-index.htm"}},{"accession":"0001213900-26-060662","ticker":"TNON","company_name":"Tenon Medical, Inc.","filed_at":"2026-05-22T21:15:15+00:00","headline":"Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060662","json":"https://secwatch.observer/filing/0001213900-26-060662.json","markdown":"https://secwatch.observer/filing/0001213900-26-060662.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/0001213900-26-060662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/ea0291962-8k_tenon.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing\nQualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that\nthe Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued\nnon-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company\nplans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s\nsecuri","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/0001493152-26-001971-index.htm","comparable_excerpt":"May 21, 2026, Tenon Medical, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying\nthe Company that it is no longer in compliance with the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/0001213900-26-060662-index.htm"}},{"accession":"0001213900-26-060267","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-05-22T01:40:52+00:00","headline":"AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K","event_type":"other_material","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060267","json":"https://secwatch.observer/filing/0001213900-26-060267.json","markdown":"https://secwatch.observer/filing/0001213900-26-060267.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/0001213900-26-060267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/ea0291955-8k_allinfuture.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing\nQualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that\nthe Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued\nnon-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company\nplans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s\nsecuri","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/0001493152-26-001971-index.htm","comparable_excerpt":"May 19, 2026, All In FutureTech Alliance,\nInc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”)\nfrom the Listing Qualifications Department (the “Staff”) of","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/0001213900-26-060267-index.htm"}},{"accession":"0001829126-26-005568","ticker":"PMI","company_name":"Picard Medical, Inc.","filed_at":"2026-05-21T20:15:19+00:00","headline":"Picard Medical Q1 revenue up 85% to $1.2M; reports $1.4M negative equity, NYSE listing notices","event_type":"other_material","sec_items":["2.02","3.01","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-005568","json":"https://secwatch.observer/filing/0001829126-26-005568.json","markdown":"https://secwatch.observer/filing/0001829126-26-005568.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626005568/0001829126-26-005568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626005568/picardmedical_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing\nQualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that\nthe Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued\nnon-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company\nplans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s\nsecuri","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/0001493152-26-001971-index.htm","comparable_excerpt":"reviously disclosed, on May\n8, 2026, the Company received a notice that it was not in compliance with Section 1003(a)(ii) (the “May 8 Notice,” and together\nwith the May 15 Notice, the “ Notices ”). In connection with the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626005568/0001829126-26-005568-index.htm"}},{"accession":"0001213900-26-059270","ticker":"XXI","company_name":"Twenty One Capital, Inc.","filed_at":"2026-05-20T12:49:08+00:00","headline":"Tether International acquires SoftBank's stake in Twenty One Capital; board members resign","event_type":"other_material","sec_items":["1.02","3.01","5.02","8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-059270","json":"https://secwatch.observer/filing/0001213900-26-059270.json","markdown":"https://secwatch.observer/filing/0001213900-26-059270.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/0001213900-26-059270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/ea0291071-8k_twenty.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing\nQualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that\nthe Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued\nnon-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company\nplans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s\nsecuri","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/0001493152-26-001971-index.htm","comparable_excerpt":"o independent directors, the minimum number required during the transition period\nfor compliance with Section 303A.07(a) of the NYSE Listed Company Manual, as provided in Section 303A.00 of the NYSE Listed Company Manual","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/0001213900-26-059270-index.htm"}},{"accession":"0001493152-26-024495","ticker":"SOPA","company_name":"SOCIETY PASS INCORPORATED.","filed_at":"2026-05-20T10:05:33+00:00","headline":"Society Pass receives Nasdaq delisting notice after filing Chapter 11 bankruptcy","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-024495","json":"https://secwatch.observer/filing/0001493152-26-024495.json","markdown":"https://secwatch.observer/filing/0001493152-26-024495.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817511/000149315226024495/0001493152-26-024495-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817511/000149315226024495/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing\nQualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that\nthe Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued\nnon-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company\nplans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s\nsecuri","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/0001493152-26-001971-index.htm","comparable_excerpt":"May 14, 2026, the Company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nthat Nasdaq had determined to delist the Company’s common stock, par value $0.0001 per share (the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1817511/000149315226024495/0001493152-26-024495-index.htm"}},{"accession":"0001193125-26-230708","ticker":"BTM","company_name":"Bitcoin Depot Inc.","filed_at":"2026-05-19T20:01:24+00:00","headline":"Bitcoin Depot files Chapter 11; Nasdaq to suspend BTM stock and warrants on May 26","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.95,"calibrated_materiality_score":0.95,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-230708","json":"https://secwatch.observer/filing/0001193125-26-230708.json","markdown":"https://secwatch.observer/filing/0001193125-26-230708.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1901799/000119312526230708/0001193125-26-230708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1901799/000119312526230708/d228011d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing\nQualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that\nthe Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued\nnon-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company\nplans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s\nsecuri","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/0001493152-26-001971-index.htm","comparable_excerpt":"May 18, 2026, the Company received a letter from the Listing Qualifications Department staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Debtors’ commencement of the Chapter 1","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1901799/000119312526230708/0001193125-26-230708-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}